PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.59M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
17.79%
Revenue growth above 1.5x MCHP's 0.57%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
39.45%
Gross profit growth above 1.5x MCHP's 0.34%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
272.17%
EBIT growth above 1.5x MCHP's 14.28%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
3330.00%
Operating income growth above 1.5x MCHP's 0.63%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
1429.41%
Positive net income growth while MCHP is negative. John Neff might see a big relative performance advantage.
2000.00%
EPS growth of 2000.00% while MCHP is zero. Bruce Berkowitz would see if minimal gains can accelerate over time.
1900.00%
Diluted EPS growth of 1900.00% while MCHP is zero. Bruce Berkowitz would see if minimal gains can be scaled further for a bigger lead.
-0.63%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
-0.39%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
-0.80%
Dividend reduction while MCHP stands at 6.08%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
121.91%
OCF growth above 1.5x MCHP's 17.30%. David Dodd would confirm a clear edge in underlying cash generation.
144.71%
Positive FCF growth while MCHP is negative. John Neff would see a strong competitive edge in net cash generation.
29.78%
10Y revenue/share CAGR under 50% of MCHP's 143.08%. Michael Burry would suspect a lasting competitive disadvantage.
5.55%
5Y revenue/share CAGR under 50% of MCHP's 78.80%. Michael Burry would suspect a significant competitive gap or product weakness.
-18.54%
Negative 3Y CAGR while MCHP stands at 35.34%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
128.04%
10Y OCF/share CAGR under 50% of MCHP's 436.49%. Michael Burry would worry about a persistent underperformance in cash creation.
53.26%
Below 50% of MCHP's 108.66%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
6.84%
3Y OCF/share CAGR under 50% of MCHP's 51.00%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
-0.33%
Negative 10Y net income/share CAGR while MCHP is at 303.26%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-17.92%
Negative 5Y net income/share CAGR while MCHP is 134.26%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-86.65%
Negative 3Y CAGR while MCHP is 31.54%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
73.41%
Below 50% of MCHP's 166.79%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
3.13%
Positive 5Y equity/share CAGR while MCHP is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
-11.69%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
417.19%
Dividend/share CAGR of 417.19% while MCHP is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
423.04%
Below 50% of MCHP's 1311.64%. Michael Burry worries the firm returns far less capital to shareholders over 5 years.
262.50%
3Y dividend/share CAGR above 1.5x MCHP's 170.92%. David Dodd sees a superior short-term capital return strategy if supported by stable earnings.
10.58%
Our AR growth while MCHP is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
-3.19%
Inventory is declining while MCHP stands at 0.82%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-0.09%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
0.66%
Positive BV/share change while MCHP is negative. John Neff sees a clear edge over a competitor losing equity.
No Data
No Data available this quarter, please select a different quarter.
-4.40%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
7.21%
SG&A growth well above MCHP's 0.48%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.